Previous 10 | Next 10 |
- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance - - Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance - - Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive - - Company Expect...
Therapeutics MD (NASDAQ: TXMD ) is scheduled to announce Q4 earnings results on Thursday, February 20th, before market open. The consensus EPS Estimate is -$0.19 (-11.8% Y/Y) and the consensus Revenue Estimate is $12.82M (+151.4% Y/Y). Over the last 2 years, TXMD has beaten EPS estima...
TherapeuticsMD (NASDAQ: TXMD) is a small-cap pharmaceutical stock that focuses on women's health issues. The company is still in its early growth stages, but with three products already in its portfolio, it could be an attractive growth opportunity for investors today. The stock has been st...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, and Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the public health system, announced today that they have entered into an agreement to expand access to ANNOVERA® (segestero...
Management cares about only one thing. Paperwork. They will forgive almost anything else - cost overruns, gross incompetence, criminal indictments - as long as the paperwork's filled out properly. And in on time. ”― Connie Willis, Bellwether Today, we take a look at a small ...
-Executive Management to Host Conference Call on February 20, 2020 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2019 financial results on Thursday, February 20, 2020, before t...
Supplement new drug application for Bijuva is submitted. Bijuva is the first and only FDA approved (on October 28 of 2018) hormone therapy of bio-identical estradiol in combination with bio-identical progesterone (P+E, 1 mg/100 mg) for the treatment of moderate to severe vasomotor symptoms due t...
TherapeuticsMD (NASDAQ: TXMD ) has submitted a New Drug Application prior-approval efficacy supplement for BIJUVA 0.5 mg/100 mg (estradiol and progesterone) capsules to the FDA late January 2020. More news on: TherapeuticsMD, Inc., Healthcare stocks news, Read more ...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today that it submitted a New Drug Application prior-approval efficacy supplement for BIJUVA 0.5 mg/100 mg (estradiol and progesterone) capsules to the U.S. Food and Drug Administration (FDA) late ...
Will The Names On This List Of Penny Stocks Rally Higher This Week? One of the most important things to keep in mind about penny stocks is that investors can make massive returns from only a small investment. On the other hand, that can work against investors as well. Since these stocks gene...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...